Format

Send to

Choose Destination
Onkologie. 2006 Dec;29(12):572-4. Epub 2006 Dec 11.

Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.

Author information

1
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. holger.hof@med.uni-heidelberg.de

Abstract

BACKGROUND:

Chordomas are rare tumors of the skull base and the spine. Treatment is difficult since conventional radiotherapy or chemotherapy have only limited effects.

PATIENT AND METHODS:

A patient with a sacral chordoma and pulmonary metastases received initial surgery and radiotherapy for a local recurrence. After 11 months another local recurrence as well as a progression of the pulmonary metastases was documented. As tumor biopsies revealed the expression of the EGF receptor an individual treatment approach with a combination of cetuximab and gefitinib was performed.

RESULTS:

Under the treatment with cetuximab/gefitinib the local recurrence and the pulmonary metastases showed a partial response over the follow-up period of 9 months. To date no treatment failure was observed.

CONCLUSIONS:

The inhibition of the EGF pathway seems to be an effective measure in the treatment of a chordoma. Further follow-up will have to prove the long-term efficiency.

PMID:
17202828
DOI:
10.1159/000096283
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center